Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2007-08-07
2007-08-07
Prouty, Rebecca E. (Department: 1652)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S226000, C435S219000, C530S350000
Reexamination Certificate
active
11090866
ABSTRACT:
Disclosed are various forms of an active, isolated β-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (β-APPwt and β-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate β-secretase. Inhibitors of β-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.
REFERENCES:
patent: 5424205 (1995-06-01), Dovey et al.
patent: 5455169 (1995-10-01), Mullan
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5733768 (1998-03-01), Dixon et al.
patent: 5744346 (1998-04-01), Chrysler et al.
patent: 5750349 (1998-05-01), Suzuki et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5795963 (1998-08-01), Mullan
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5849560 (1998-12-01), Abraham
patent: 5863756 (1999-01-01), Barr et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6025180 (2000-02-01), Powell et al.
patent: 6162630 (2000-12-01), Powell et al.
patent: 6211428 (2001-04-01), Singh et al.
patent: 6221645 (2001-04-01), Chrysler et al.
patent: 6245884 (2001-06-01), Hook
patent: 6245964 (2001-06-01), McConlogue et al.
patent: 6313268 (2001-11-01), Hook
patent: 6319489 (2001-11-01), Powell et al.
patent: 6319689 (2001-11-01), Powell et al.
patent: 6329163 (2001-12-01), Anderson et al.
patent: 6358725 (2002-03-01), Christie et al.
patent: 6361975 (2002-03-01), Christie et al.
patent: 6420534 (2002-07-01), Gurney et al.
patent: 6440698 (2002-08-01), Gurney et al.
patent: 6500667 (2002-12-01), Gurney et al.
patent: 6627739 (2003-09-01), Anderson et al.
patent: 6699671 (2004-03-01), Gurney et al.
patent: 6706485 (2004-03-01), Gurney et al.
patent: 6727074 (2004-04-01), Gurney et al.
patent: 6737510 (2004-05-01), Gurney et al.
patent: 6753163 (2004-06-01), Gurney et al.
patent: 6790610 (2004-09-01), Gurney et al.
patent: 6797487 (2004-09-01), Gurney et al.
patent: 6825023 (2004-11-01), Gurney et al.
patent: 6828117 (2004-12-01), Gurney et al.
patent: 6835565 (2004-12-01), Gurney et al.
patent: 6844148 (2005-01-01), Gurney et al.
patent: 6852482 (2005-02-01), Gurney et al.
patent: 2001/0021391 (2001-09-01), Gurney et al.
patent: 2002/0037315 (2002-03-01), Gurney et al.
patent: 2002/0081634 (2002-06-01), Gurney et al.
patent: 2004/0043408 (2004-03-01), Gurney et al.
patent: 2004/0048303 (2004-03-01), Gurney et al.
patent: 2004/0166507 (2004-08-01), Gurney et al.
patent: 2004/0234976 (2004-11-01), Gurney et al.
patent: 848 062 (1998-06-01), None
patent: 855 442 (1998-07-01), None
patent: 855 444 (1998-07-01), None
patent: 1 445 263 (2004-08-01), None
patent: 2 364 059 (2004-01-01), None
patent: 2 389 113 (2004-02-01), None
patent: 2 389 114 (2004-02-01), None
patent: 2 389 182 (2004-02-01), None
patent: WO 96/20725 (1996-07-01), None
patent: WO 96/31122 (1996-10-01), None
patent: WO 96/40885 (1996-12-01), None
patent: WO 97/47314 (1997-12-01), None
patent: WO 98/11236 (1998-03-01), None
patent: WO 98/13488 (1998-04-01), None
patent: WO 98/21589 (1998-05-01), None
patent: WO 98/26059 (1998-06-01), None
patent: WO 98/37226 (1998-08-01), None
patent: WO 99/31236 (1999-06-01), None
patent: WO 99/34004 (1999-08-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 99/64587 (1999-12-01), None
patent: WO 00/17369 (2000-03-01), None
patent: WO 00/23576 (2000-04-01), None
patent: WO 00/47618 (2000-08-01), None
patent: WO 00/56871 (2000-09-01), None
patent: WO 00/58479 (2000-10-01), None
patent: WO 00/68266 (2000-11-01), None
patent: WO 00/69262 (2000-11-01), None
patent: WO 01/00663 (2001-01-01), None
patent: WO 01/00665 (2001-01-01), None
patent: WO 01/23533 (2001-04-01), None
patent: WO 01/29563 (2001-04-01), None
patent: WO 01/31054 (2001-05-01), None
patent: WO 01/36600 (2001-05-01), None
patent: WO 01/38487 (2001-05-01), None
patent: WO 01/49097 (2001-07-01), None
patent: WO 01/49098 (2001-07-01), None
patent: WO 01/50829 (2001-07-01), None
Kuntz I. Structure-Based Strategies for Drug Design and Discovery, Science, 1992, 257, 1078-1082.
Baldwin et al., “Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design,”PNAS, 90:6796-6800 (1993).
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Research, 10:398-400 (2000).
Broun et al., “Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity,”Science, 282:131-133 (1998).
Brown et al., “Evaluation of Cathepsins D and G and EC 3.4.24.15 as Candidate β-Secretase Proteases Using Peptide and Amyloid Precursor Protein Substrates,”Journal of Neurochemistry, 66:2436-2445 (1996).
Chevallier et al., “Cathepsin D displays in vitro β-secretase-like specificity,”Brain Research, 750:11-19 (1997).
Chyung et al., “Novel β-Secretase Cleavage of β-Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells,”Journal of Cell Biology, 138:671-680 (1997).
Das et al., “Estrogenic responses in estrogen receptor-α deficient mice reveal a distinct estrogen signaling pathway,”PNAS, 94:12786-12791 (1997).
Declaration of Michael Bienkowski, Ph.D. in U.S. Appl. No. 09/548,368.
Dennis et al., “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa,”J. Biol. Chem., 269(35):22129-22136 (1994).
Diedrich et al., “Nucleotide sequence of a cDNA encoding mouse cathepsin D,”Nucleic Acids Research, 18:7184 (1990).
Elan Corporation, plc and Pharmacia Corporation announce research collaboration, News Aug. 9, 2000, www.elancorp.com.
Evin et al., “Alzheimer's disease amyloid precursor protein (βAPP): proteolytic processing, secretases and βA4 amyloid production,”Amyloid; Int. J. Exp. Clin. Invest. 1:263-280 (1994).
Haass et al., “Amyloid β-peptide is Produced by Cultured Cells During Normal Metabolism,”Nature, 359:322-325 (1992).
Haass et al., “The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β-Secretase Cleavage Within the Secretory Pathway,”Nature Medicine, 12:1291-1296 (1995).
Haass et al., “β-Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms,”Journal of Biochemistry, 268:3021-3024 (1993).
Hardy, J., “Framing beta-amyloid,”Nature Genetics, 1(4):233-234 (1992).
Hirosawa et al., “Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain,”DNA Res., 6(5):329-336 (1999).
Hussain et al., “Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase,”Molecular and Cellular Neuroscience, 14:419-427 (1999).
Jackson et al., “The p47phoxMouse Knock-Out Model of Chronic Granulomatous Disease,”J. Exp. Med., 182:751-758 (1995).
Kang et al., “The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor,”Nature, 325:733-736 (1987).
Kick et al., “Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D,”Chem.&Biol., 4:297-307 (1997).
Kitaguchi et al., “Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity,”Nature, 331:530-532 (1988).
Knops et al., “Cell-type and Amyloid Precursor Protein-type Specific Inhibition of Aβ Release by Barfilomycin A1, a Selective Inhibitor of Vacuolar ATPases,”Journal of Biological Chemistry, 270:2419-2422 (1995).
Koo et al., “Evidence that Production and Release of Amyloid β-Protein Involves the Endocytic Pathway,”
Anderson John P.
Basi Guriqbal
Doan Minh Tam
Frigon Normand
John Varghese
Elan Pharmaceuticals Inc.
Prouty Rebecca E.
Walicka Malgorzata A.
LandOfFree
β-secretase enzyme compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with β-secretase enzyme compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-secretase enzyme compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3830041